Clinical Trial Detail

NCT ID NCT03630120
Title Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

thyroid gland cancer

Therapies

Lenvatinib + Sorafenib

Cabozantinib + Vandetanib

Age Groups: adult senior

No variant requirements are available.